Compare Equinor ASA (EQNR) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Viatris Inc — how do they compare? Equinor ASA trades at $40.77 (market cap $97.58B), while Viatris Inc trades at $16.25 (market cap $18.69B). The key difference: Equinor ASA is far larger — about 5.2× Viatris Inc's market cap, and Equinor ASA pays the higher dividend (3.81%). Which is the better fit depends on your goals.
| EQNR | VTRS | |
|---|---|---|
Market Cap | $97.58B | $18.69B |
Sector | Energy | Health |
52-Week High | $42.40 | $17.86 |
52-Week Low | $22.41 | $9.49 |
Enterprise Value | $106.28B | $30.80B |
Dividend Yield | 3.81% | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EQNR trades at $40.99, up 5.32% over 24 hours, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 40% year-over-year despite an earnings miss, driven by higher energy prices and production. Recent news highlights a 22.2% monthly rally and ongoing share buybacks. Valuation ratios appear attractive with a P/E of 11.09 and EV/EBITDA of 2.3, while profitability metrics like a 21.32% ROE indicate efficient capital use.
The outlook for EQNR is positive, with opportunities from strategic investments in subsea projects and sustained cash flow generation supporting dividends and buybacks. Risks include volatility in oil and gas prices, execution challenges in growth projects, and potential regulatory shifts impacting energy markets. Analyst sentiment is mixed but leans cautious, with 56.53% holding a neutral stance amid valuation concerns after recent gains.
Viatris (VTRS) trades at $16.28, down 0.91% on the day, with a bearish technical signal and mixed fundamentals. The company reported a net loss of $3.51 billion in 2025 despite recent quarterly earnings beats, including Q2 2026 EPS of $0.69 versus $0.62 expected. Revenue declined to $14.30 billion in 2025, but operational cash flow remains strong at $2.32 billion. Recent news highlights divestitures and FDA approval for Gwyn Lo, a contraceptive patch.
Outlook is cautious due to persistent losses and high P/E of 236.2, but dividend payments and cost-cutting efforts offer stability. Risks include competitive pressures and debt levels, while analyst consensus leans hold. The stock's value hinges on margin improvement and debt reduction progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
